Skip to content
Nulojix(belatacept)
Nulojix (belatacept) is a protein pharmaceutical. Belatacept was first approved as Nulojix on 2011-06-15. It has been approved in Europe to treat graft rejection and kidney transplantation. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
therapeuticsD013812
operative surgical proceduresD013514
immune system phenomenaD055633
Trade Name
FDA
EMA
Nulojix
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Belatacept
Tradename
Proper name
Company
Number
Date
Products
NulojixbelataceptBristol-Myers Squibb CompanyN-125288 RX2011-06-15
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
nulojixBiologic Licensing Application2018-04-13
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
belatacept, Nulojix, Bristol-Myers Squibb Company
2118-06-15Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AA: Selective immunosuppressants
L04AA28: Belatacept
HCPCS
Code
Description
J0485
Injection, belatacept, 1 mg
Clinical
Clinical Trials
252 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.991331211989
Kidney transplantationD0160303835321
Chronic kidney failureD007676EFO_0003884N18.6213117
Psoriatic arthritisD015535EFO_0003778L40.51214
DermatomyositisD003882EFO_0000398M3311114
Graft rejectionD006084213
TransplantationD014180112
Epstein-barr virus infectionsD020031EFO_000076911
Rheumatic diseasesD012216M79.011
Biliary liver cirrhosisD008105K74.311
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M321616
Juvenile arthritisD001171EFO_0002609M0844
Covid-19D000086382U07.11213
Lupus nephritisD008181EFO_00057611113
Giant cell arteritisD013700EFO_1001209M31.6123
Sjogren's syndromeD012859EFO_0000699M35.0123
Granulomatosis with polyangiitisD014890EFO_0005297M31.31213
Anti-neutrophil cytoplasmic antibody-associated vasculitisD056648I77.82213
NeoplasmsD009369C80112
Myelodysplastic syndromesD009190D46112
Show 13 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E102618
Graft vs host diseaseD006086D89.81478
PsoriasisD011565EFO_0000676L40224
Interstitial lung diseasesD017563EFO_0004244J84.8933
Immunosuppression therapyD007165112
Heart transplantationD016027EFO_001067322
Delayed graft functionD051799112
UveitisD014605EFO_1001231H20.922
Diffuse sclerodermaD045743EFO_0000404122
Alopecia areataD000506EFO_0004192L6322
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Renal insufficiencyD051437HP_0000083N19112
Sickle cell anemiaD000755EFO_0000697D5722
Mucopolysaccharidosis iD008059E76.011
Aplastic anemiaD000741HP_0001915D61.911
Beta-thalassemiaD017086Orphanet_848D56.111
Wiskott-aldrich syndromeD014923D82.011
Hemophagocytic lymphohistiocytosisD051359D76.111
Diamond-blackfan anemiaD029503D61.0111
Shwachman-diamond syndromeD00008100311
Show 13 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Islets of langerhans transplantationD01638111
Chronic hepatitis bD019694EFO_0004197B18.111
Gaucher diseaseD005776Orphanet_355E75.2211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBELATACEPT
INNbelatacept
Description
Belatacept (immunoadhesin)
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: T-cell receptors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID706808-37-9
RxCUI1112973
ChEMBL IDCHEMBL1742990
ChEBI ID
PubChem CID
DrugBankDB06681
UNII IDE3B2GI648A (ChemIDplus, GSRS)
Target
Agency Approved
CD80
CD80
CD86
CD86
Organism
Homo sapiens
Gene name
CD80
Gene synonyms
CD28LG, CD28LG1, LAB7
NCBI Gene ID
Protein name
T-lymphocyte activation antigen CD80
Protein synonyms
Activation B7-1 antigen, B-lymphocyte activation antigen B7, B7, BB1, CD80, CD80 antigen (CD28 antigen ligand 1, B7-1 antigen), costimulatory factor CD80, costimulatory molecule variant IgV-CD80, CTLA-4 counter-receptor B7.1
Uniprot ID
Mouse ortholog
Cd80 (12519)
T-lymphocyte activation antigen CD80 (Q61332)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Nulojix - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,251 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nulojix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
720 adverse events reported
View more details